Martin Gleave, MD, FRCSC, FACS, explains how the adaptive, biomarker-driven GUNS trial uses neoadjuvant therapy to link genomic subtypes with treatment response.
Martin Gleave, MD, FRCSC, FACS
Advertisement
Articles by Martin Gleave, MD, FRCSC, FACS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
The ArteraAI Prostate Test: What It Is and How It Works
2
HHS requests testosterone therapy label updates, citing new safety data
3
Retrospective study suggests differences in OAB therapy persistence among older adults
4
Unmet needs and emerging solutions in MRI-guided prostate cancer care
5